Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer

Published:2015-10-29 Issue:4 Volume:5 Page:e1102828
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Chellappa Stalin,Hugenschmidt Harald,Hagness Morten,Line Pål D.,Labori Knut J.,Wiedswang Gro,Taskén Kjetil,Aandahl Einar M.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1102828

Reference54 articles.

1. FOXP3+ regulatory T cells in the human immune system

2. Basic principles of tumor-associated regulatory T cell biology

3. Human FOXP3 and cancer

4. Inflammation Versus Adaptive Immunity in Cancer Pathogenesis

5. The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focus on Pancreatic Cancer Microenvironment;Current Oncology;2024-07-26

2. Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer;International Journal of Molecular Sciences;2024-07-24

3. Current and future immunotherapeutic approaches in pancreatic cancer treatment;Journal of Hematology & Oncology;2024-06-04

4. Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?;Frontiers in Immunology;2024-05-30

5. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma;Journal for ImmunoTherapy of Cancer;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3